JAK2 and anemia: There are still limitations in targeting JAK2 that are mainly caused by the dependency of normal hematopoiesis on JAK2, resulting in a specific toxicity expressed as the combination of anemia and thrombocytopenia in patients with MF treated with JAK2 inhibitors [34].